Pipeline

ARN-6039
Our lead agent in clinical development, ARN-6039, is an oral and selective small molecule antagonist of Retinoic acid-related orphan nuclear receptor gt (RORgt)/ RORg

RORgt is the key transcription factor and is the master regulator of human Th17 (T helper 17) cells, a unique subset of CD4+T cells. RORgt controls cellular differentiation, function and InterleukinIL-17 (IL-17 producing T-helper lymphocytes) release by Th17 cells and helps mediate the immunopathology of human autoimmune diseases such as Psoriasis (PsO), Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Colitis, Asthma, Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO).

ARN-6039/BOS-172767 Most Recent Events:
  • March 21, 2018: A Phase 1 New Formulation Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, PPI Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects.
  • June 28, 2017: ARN-6039 licensed to Boston Pharmaceuticals.
  • February 16, 2017: ARN-6039 Phase 1 clinical trials completed.
  • May 16, 2016: Arrien Pharmaceuticals initiated the Phase 1 Clinical Trials for Safety, Tolerability and Pharmacokinetics profile in Healthy Subjects.
  • April 29, 2016: FDA accepted ARN-6039 IND to begin a Phase 1 clinical trials.
ARN-6039/BOS-172767: Clinical Trials
  • Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects (NCT03464058)
  • A Phase 1 Study of ARN-6039 (ARN-6039) (NCT03237832)